PUBLISHER: The Business Research Company | PRODUCT CODE: 1942757
PUBLISHER: The Business Research Company | PRODUCT CODE: 1942757
Drug delivery systems are innovative technologies or methods developed to transport therapeutic agents within the body in a controlled and efficient way. These systems are designed to improve treatment effectiveness and safety by controlling the rate, timing, and location of drug release. They help maintain optimal drug concentrations at target sites, minimize side effects, and enhance patient adherence to prescribed treatments.
The primary categories of drug delivery systems include injection-based drug delivery systems, oral drug delivery systems, inhalation or pulmonary drug delivery systems, and transmucosal drug delivery systems. Injection-based drug delivery systems are medical devices used to administer drugs into the body via various injection routes, utilizing tools such as syringes, needles, or auto-injectors for precise and targeted delivery. These systems can be made from different material types, including polymer-based, lipid-based, inorganic, biologics-based, and hybrid drug delivery systems. They are used to treat conditions such as infectious diseases, cancer, eye disorders, urinary diseases, diabetes, central nervous system disorders, and more. Key end-users of these systems include hospitals, pharmaceutical companies, research institutions, homecare providers, and diagnostic laboratories.
Tariffs are impacting the drug delivery systems market by increasing costs of imported polymers, lipids, and biologics used in manufacturing advanced delivery devices. Segments such as polymer-based systems, inhalers, and needle-free injectors are most affected, particularly in Asia-Pacific regions including China and India, major manufacturing hubs. This has led to higher production costs and delayed product launches. Positively, tariffs have encouraged local production, innovation in alternative materials, and investment in domestic manufacturing capabilities.
The drug delivery systems market research report is one of a series of new reports from The Business Research Company that provides drug delivery systems market statistics, including drug delivery systems industry global market size, regional shares, competitors with a drug delivery systems market share, detailed drug delivery systems market segments, market trends and opportunities, and any further data you may need to thrive in the drug delivery systems industry. This drug delivery systems market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The drug delivery systems market size has grown strongly in recent years. It will grow from $44.21 billion in 2025 to $47.54 billion in 2026 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to reliance on conventional oral and injectable delivery, limited biologics formulations, growing hospital and clinical infrastructure, increasing chronic disease prevalence, rising r&d in pharmaceuticals.
The drug delivery systems market size is expected to see strong growth in the next few years. It will grow to $62.89 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to advancement in polymer and lipid-based delivery systems, growth of personalized medicine, increasing use of inhalation and transmucosal delivery, rising adoption of homecare and self-administration devices, integration of digital monitoring and smart delivery technologies. Major trends in the forecast period include rising adoption of targeted and controlled drug release technologies, increasing development of biologics and advanced therapeutics, growth in homecare drug delivery solutions, expansion of minimally invasive and needle-free delivery systems, enhanced focus on patient compliance and safety.
The rising prevalence of respiratory disorders is expected to drive the growth of the drug delivery systems market in the coming years. Respiratory disorders are conditions that disrupt the normal function of the lungs and airways, causing breathing difficulties and reduced oxygen intake. The increase in these disorders is largely due to escalating air pollution, which exposes people to harmful airborne particles and gases that damage lung function and contribute to the onset and progression of respiratory diseases. Drug delivery systems play a vital role in the effective treatment and management of respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and cystic fibrosis. These systems enable medications to be delivered directly to the lungs, improving therapeutic effectiveness while reducing systemic side effects. For example, in March 2025, the UK Health Security Agency-a government body in the UK-reported that tuberculosis cases in England rose by 13% in 2024, increasing from 4,850 cases in 2023 to 5,480 cases. Consequently, the growing prevalence of respiratory disorders is expected to propel the drug delivery systems market.
Key players in the drug delivery systems market are concentrating on developing advanced solutions like metal-free, multidose nasal spray pumps to enhance user comfort and ease of use. These metal-free, multidose nasal spray pumps are designed to administer multiple medication doses through the nasal route without incorporating any metal parts, ensuring safety and compatibility with various formulations. For example, in January 2023, Aptar Pharma, a pharmaceutical company based in the U.S., introduced the APF Futurity metal-free, multidose nasal spray pump. This device is specifically engineered for delivering nasal saline and similar over-the-counter products, with a strong emphasis on recyclability. It is Aptar Pharma's first highly recyclable nasal spray pump, earning a Class AA certification from cyclos-HTP for European recycling standards. Constructed entirely from polyolefin materials and free from metal components or recycling contaminants, it facilitates easier recycling and enhances the quality of recycled materials. Incorporating Aptar Pharma's Advanced Preservative Free technology, this metal-free pump provides precise and consistent dosing with smooth operation, maintaining ease of use and effectiveness.
In January 2024, Kindeva Drug Delivery, a U.S.-based contract development and manufacturing organization, acquired Summit Biosciences Inc. for an undisclosed sum. This acquisition expanded Kindeva's drug delivery capabilities by adding a new platform. It enables the company to provide biopharmaceutical clients with a broader portfolio of advanced drug-device combination products, including those for pulmonary, injectable, transdermal, and nasal delivery. Summit Biosciences Inc. is a U.S.-based contract development and manufacturing firm specializing in intranasal drug delivery.
Major companies operating in the drug delivery systems market are Pfizer Inc., Johnson & Johnson, F. Hoffmann La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories Inc., Novartis AG, GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Becton Dickinson and Company, Teva Pharmaceutical Industries Ltd., Tandem Diabetes Care, Pacira Biosciences Inc., Universal Stabilization Technologies Inc., Spectrum Pharmaceuticals Inc., West Pharmaceutical Services Inc., Catalent Inc., Recipharm AB
North America was the largest region in the drug delivery system market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug delivery systems market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the drug delivery systems market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The drug delivery systems market consists of sales of implantable devices, targeted delivery carriers, nanoparticle-based systems, and bio adhesive systems. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Drug Delivery Systems Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses drug delivery systems market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for drug delivery systems ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The drug delivery systems market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.